MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC. - Azuma, K.; Imai, H.; Yamaguchi, T.; Kijima, T.; Kishi, K.; Fujita, K.; Saito, H.; Shiraishi, Y.; Tanizaki, J.; Takashima, Y.; Tambo, Y.; Watanabe, S.; et al. (Annals of Oncology, 2024)